As reported in 1994, the original SOD1-G93A strain, designated G1, expressed approximately 18 copies of human SOD1, randomly inserted into the genome (Gurney et al., 1994). An unequal crossover event ...

Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders. Companies have moved a PET ligand into Phase 1 trials.

Background Sensory Stimulation Systems, and GENUS, refer to a noninvasive procedure, i.e., a "digital therapeutic," being developed by Cognito Therapeutics. The company developed a wearable GammaSense ...

If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...

The Alzheimer’s field begins 2021 with a glimmer of good news: Donanemab, a monoclonal antibody that recognizes a pyroglutamated form of Aβ, slowed cognitive decline in people with early AD. That was ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

After years of fits and starts, anti-amyloid immunotherapies are finally hitting their target effectively. At least four drugs have now demonstrated the ability to clear plaques from the brain: ...

Lecanemab may soon become widely available; Eisai/Biogen have begun submitting data to the Food and Drug Administration to support its accelerated approval (Oct 2021 news). In the meantime, studies ...

Michelle Mielke at Wake Forest University in Winston-Salem, North Carolina, noted that women’s higher risk is likely to have multiple causes. “Hormones are a contributor, but there are a lot of other ...

In these two Phase 3 studies, the incidence of ARIA rose with dose. At 10 mg/kg—the dosage approved for clinical use—35 percent of participants developed the edema known as ARIA-E. This compared to an ...

In the U.S. data, the three most prevalent factors—obesity, hypertension, physical inactivity—also had the largest PAF, each accounting for 20 percent of dementia risk (see image below). Other common ...